Therefore, SGLT2 inhibitors are recommended as first-choice, independently of glucose control or other concomitant glucose-lowering treatment, in individuals with diabetes and HF, to reduce the rate of HF-related events. Here, SLC5A2 is linked to diabetes mellitus.